Compare Franklin FTSE South Korea ETF (FLKR) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

FLKR (Franklin FTSE South Korea ETF) is trading at $54.89, down 2.03% with a bearish technical signal (16 sell vs 6 buy signals). The ETF faces pressure from semiconductor sector volatility and rising global yields, though some analysts see current levels as a potential buying opportunity. Technical indicators show strong resistance at $55-$56 with support at $53-$54 levels. The fund remains heavily concentrated in Korean memory chip giants Samsung and SK Hynix, making it highly sensitive to AI and semiconductor cycles.

While FLKR faces near-term headwinds from semiconductor volatility and macroeconomic pressures, long-term prospects remain tied to AI-driven demand for Korean tech. The current discount to growth expectations presents opportunity, but investors must weigh concentration risk against potential semiconductor recovery. Key risks include political tensions, currency fluctuations, and global interest rate environment.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.